

Special Issue

Targeting KRAS in Lung Cancer: Current Status and Future Directions

Message from the Guest Editor

The Special Issue aims to provide a comprehensive overview of the latest advances and challenges in targeting KRAS-driven lung cancers. KRAS mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC), yet they have historically posed significant therapeutic challenges. With the recent approval of KRAS G12C inhibitors and ongoing development of novel therapeutic strategies, this issue seeks to explore the evolving landscape of KRAS-targeted therapies in both early and advanced disease settings. Topics of interest include molecular diagnostics, mechanism-based therapeutics, resistance mechanisms, combination therapies, and real-world clinical outcomes. We also welcome contributions on biomarker development, translational research, and innovative trial designs that may shape future directions in KRAS-mutant lung cancer management. This issue emphasizes stage-dependent treatment strategies, molecular characterization, and the integration of systemic therapies to improve patient survival and quality of life.

Guest Editor

Dr. Sally Lau

NYU Langone Health, 550 1st Ave, New York, NY 10016, USA

Deadline for manuscript submissions

30 June 2026



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/255565

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
 2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada
-

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)